Aridis Pharmaceuticals Inc. Common Stock
ARDS
ARDS was delisted on the 18th of July, 2023.
20 hedge funds and large institutions have $2.96M invested in Aridis Pharmaceuticals Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 6 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 1
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
11% more funds holding
Funds holding: 18 → 20 (+2)
7.39% less ownership
Funds ownership: 16.43% → 9.04% (-7.4%)
60% less capital invested
Capital invested by funds: $7.33M → $2.96M (-$4.37M)
96% less call options, than puts
Call options by funds: $6K | Put options by funds: $164K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$961K |
| 2 |
RAM
Roumell Asset Management
Chevy Chase,
Maryland
|
+$282K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$155K |
| 4 |
Jane Street
New York
|
+$113K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$57.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$3.93M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$554K |
| 3 |
Millennium Management
New York
|
-$274K |
| 4 |
MWM
Minot Wealth Management
Westwood,
Massachusetts
|
-$92K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.23K |
ARDS Hedge Fund Activity: Q4 2021 in Review
20 of the 6,519 institutional investors tracked by Wall St. Rank reported a position in Aridis Pharmaceuticals Inc. Common Stock (ARDS) for Q4 2021, worth a combined $2.96M — down 60% from $7.33M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ARDS positions and 6 closed out — a net gain of 2 holders — while 6 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, adding an estimated $961K. The largest seller was Armistice Capital, exiting entirely with an estimated $3.93M sold.
- 20 institutional investors held Aridis Pharmaceuticals Inc. Common Stock (ARDS) as of Q4 2021, up from 18 in Q3 2021.
- Funds reported $2.96M of Aridis Pharmaceuticals Inc. Common Stock stock for Q4 2021, down 60% quarter-over-quarter.
- 8 funds opened new Aridis Pharmaceuticals Inc. Common Stock positions in Q4 2021 and 6 closed out, a net change of +2 holders.
- The largest Aridis Pharmaceuticals Inc. Common Stock buyer in Q4 2021 was Vanguard Group, an estimated $961K added.
- The largest Aridis Pharmaceuticals Inc. Common Stock seller in Q4 2021 was Armistice Capital, an estimated $3.93M sold.
Based on aggregated 13F filings for Q4 2021.